Aida Pharmaceuticals (AIDA.OB) announced that the company’s upcoming Rh-Apo2L cancer drug has been named as one of the “New and High-Tech Transforming Products of 2007” by the Shanghai New High Technology Service Center. This Center is a special government commercialization division focused on leading innovations, run by Shanghai Municipal Government
Shanghai New High Technology Service Technology is a clearing house that allows the Chinese government to evaluate and narrow down technological candidates. In turn, these products have the greatest potential for national and global commercialization and success.
Aida Pharmaceuticals is a leading pharmaceutical company focused on the formulation, registration, and marketing of advanced pharmaceutical and genetic products in mainland China. The Company seeks to discover, acquire, and develop new therapies that improve human health. Aida is currently headquartered in Hangzhou, China.
Let us hear your thoughts below: